Shopping Cart
- Remove All
- Your shopping cart is currently empty
Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells. Gardiquimod is an imidazoquinoline analog and is a TLR7/8 agonist. When used at concentrations below 10 μM, Gardiquimod specifically activates TLR7.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $30 | In Stock | |
2 mg | $43 | In Stock | |
5 mg | $68 | In Stock | |
10 mg | $113 | In Stock | |
25 mg | $188 | In Stock | |
50 mg | Inquiry | In Stock | |
1 mL x 10 mM (in DMSO) | $81 | In Stock |
Description | Gardiquimod is a TLR7/8 agonist. When used at concentrations below 10 μM, Gardiquimod specifically activates TLR7. Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells. |
In vitro | Administration of 6-60?μM Gardiquimod obviously inhibits HIV-1 reverse transcriptase cDNA synthesis[1]. |
In vivo | Gardiquimod (1 mg/kg per mouse; i.p.; daily for 7 days) in combination with Dendritic cells (DCs) enhance the anti-tumor effects of NK cells[2]. |
Molecular Weight | 313.4 |
Formula | C17H23N5O |
Cas No. | 1020412-43-4 |
Smiles | CCNCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O |
Relative Density. | 1.29 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 45 mg/mL (143.59 mM), Sonication is recommended. DMF: 18 mg/mL (57.43 mM) | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
DMF/DMSO
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.